文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Molecular Determinants of Lung Function Decline: A Multi- Level Analysis of Gene Expression.

作者信息

Elhusseini Zaid W, Rafique Omar, Ryu Min Hyung, Castaldi Peter, Sin Don D, Ruczinski Ingo, Hersh Craig P

机构信息

Harvard Medical School.

St. Paul's Hospital, University of British Columbia.

出版信息

Res Sq. 2025 Aug 19:rs.3.rs-7292685. doi: 10.21203/rs.3.rs-7292685/v1.


DOI:10.21203/rs.3.rs-7292685/v1
PMID:40894069
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12393492/
Abstract

BACKGROUND: Chronic obstructive pulmonary disease (COPD) is characterized by progressive lung function decline, commonly measured by forced expiratory volume in one second (FEV). Uncovering the genetic basis of FEV decline is essential for understanding COPD pathophysiology and for developing therapies. We hypothesized that gene expression patterns in inflammatory pathways are associated with FEV decline. METHODS: We analyzed whole blood RNA-sequencing data from the 5 (n = 4,147) and 10 year visits (n = 435) in the COPDGene Study. Gene expression was assessed in three analyses: cross-sectional associations with FEV at two separate time points, association between year 5 gene expression and FEV changes from year 5-10, and longitudinal changes in both gene expression and FEV. A gene signature derived from the 5-year visit was linked to FEV decline across three intervals (baseline to 5 years, 5 to 10 years, and baseline to 10 years) and tested for validation in the ECLIPSE study. RESULTS: Distinct gene sets emerged in the three analyses (Cross-sectional: 961 genes; FEV Change: 179; Longitudinal: 532). Only two genes ( and ) overlapped across all analyses, while unique genes (e.g., , and ) were context-specific. Pathway analysis of genes from the longitudinal analysis highlighted oxidative stress and immune processes. A 20-gene signature was derived, including 17 genes positively and three negatively associated with FEV. These signatures were significantly associated with FEV-related traits in COPDGene and ECLIPSE. CONCLUSIONS: These findings reveal molecular markers of FEV decline, offering insights into COPD pathophysiology and potential therapeutic targets.

摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8a00/12393492/972036a18271/nihpp-rs7292685v1-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8a00/12393492/593ea9f4c5a4/nihpp-rs7292685v1-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8a00/12393492/528909b04a8b/nihpp-rs7292685v1-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8a00/12393492/972036a18271/nihpp-rs7292685v1-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8a00/12393492/593ea9f4c5a4/nihpp-rs7292685v1-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8a00/12393492/528909b04a8b/nihpp-rs7292685v1-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8a00/12393492/972036a18271/nihpp-rs7292685v1-f0003.jpg

相似文献

[1]
Molecular Determinants of Lung Function Decline: A Multi- Level Analysis of Gene Expression.

Res Sq. 2025-8-19

[2]
Long-acting inhaled therapy (beta-agonists, anticholinergics and steroids) for COPD: a network meta-analysis.

Cochrane Database Syst Rev. 2014-3-26

[3]
Self-management interventions for people with chronic obstructive pulmonary disease.

Cochrane Database Syst Rev. 2022-1-10

[4]
Indacaterol, a once-daily beta2-agonist, versus twice-daily beta₂-agonists or placebo for chronic obstructive pulmonary disease.

Cochrane Database Syst Rev. 2015-1-10

[5]
Umeclidinium bromide versus placebo for people with chronic obstructive pulmonary disease (COPD).

Cochrane Database Syst Rev. 2017-6-20

[6]
Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease.

Cochrane Database Syst Rev. 2014-3-10

[7]
Long-acting beta2-agonists for chronic obstructive pulmonary disease.

Cochrane Database Syst Rev. 2013-10-15

[8]
Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del).

Cochrane Database Syst Rev. 2023-11-20

[9]
Conventional chest physiotherapy compared to other airway clearance techniques for cystic fibrosis.

Cochrane Database Syst Rev. 2023-5-5

[10]
Pulmonary rehabilitation for chronic obstructive pulmonary disease.

Cochrane Database Syst Rev. 2015-2-23

本文引用的文献

[1]
Blood Gene Expression and Immune Cell Subtypes Associated with Chronic Obstructive Pulmonary Disease Exacerbations.

Am J Respir Crit Care Med. 2023-8-1

[2]
Identification of novel genetic variants, including PIM1 and LINC01491, with ICD-10 based diagnosis of pulmonary arterial hypertension in the UK Biobank cohort.

Front Drug Discov (Lausanne). 2023

[3]
Inference of chronic obstructive pulmonary disease with deep learning on raw spirograms identifies new genetic loci and improves risk models.

Nat Genet. 2023-5

[4]
Genetic diversity fuels gene discovery for tobacco and alcohol use.

Nature. 2022-12

[5]
Astegolimab, an anti-ST2, in chronic obstructive pulmonary disease (COPD-ST2OP): a phase 2a, placebo-controlled trial.

Lancet Respir Med. 2022-5

[6]
Safety and efficacy of itepekimab in patients with moderate-to-severe COPD: a genetic association study and randomised, double-blind, phase 2a trial.

Lancet Respir Med. 2021-11

[7]
Blood RNA sequencing shows overlapping gene expression across COPD phenotype domains.

Thorax. 2022-2

[8]
Inflammatory biomarker relationships with helper T cell GPR15 expression and cannabis and tobacco smoking.

J Psychosom Res. 2021-2

[9]
: batch effect adjustment for RNA-seq count data.

NAR Genom Bioinform. 2020-9

[10]
Regulatory mechanism of NOV/CCN3 in the inflammation and apoptosis of lung epithelial alveolar cells upon lipopolysaccharide stimulation.

Mol Med Rep. 2019-9-9

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索